Home » Cardiovascular » VALIANT Trial (2003): Valsartan, Captopril, or Both in Myocardial Infarction

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

VALIANT Trial (2003): Valsartan, Captopril, or Both in Myocardial Infarction

VALIANT Trial Summary visual abstract

VALIANT Trial Summary: Pfeffer et al. randomized 14,703 patients with acute MI within prior 10 days complicated by HF and/or LVEF ≤35% to either valsartan or captopril or combination of both. The objective was to assess the efficacy of ARBs compared with ACE-I in patients in the post-MI period complicated by HF and/or LV systolic dysfunction. The results of the trial showed similar mortality rates among both ACE and ARB groups along with similar rates in combination of both.  The authors of the VALIANT trial concluded that Valsartan was as effective as captopril in improving survival among patients with HF and/or LV dysfunction in the post-MI period.

Source: NEJM

Subscribe via email